Research institute launches tender for sequencing and proteomics
A research body seeks external molecular sequencing and proteomics services, signalling continued investment in high-end life science analytics.
A research body seeks external molecular sequencing and proteomics services, signalling continued investment in high-end life science analytics.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
The Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. HKI has published a contract notice for external molecular biological sequencing and proteomics services, underscoring how research organisations are increasingly buying in advanced omics capacity rather than relying solely on in-house laboratories.
On 19th March 2026, the Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. HKI issued a contract notice for the provision of molecular biological sequencing and proteomics services.
The institute’s name points to a focus on natural product research and infection biology. For that kind of work, the ability to profile both genetic material and proteins is central to understanding how pathogens behave and how host organisms respond. By seeking a combined package of sequencing and proteomics, the buyer signals a need for integrated molecular analysis rather than isolated tests.
The notice is concise and does not spell out volumes, platforms or disease areas. What it makes clear is that the institute wants specialist providers to supply these capabilities as services, rather than procuring specific instruments itself. That leaves room for a broad range of laboratory and bioanalytical providers to position themselves, from core sequencing facilities to contract research organisations.
Although brief, the description brings together two powerful techniques. Sequencing services point to detailed analysis of nucleic acids, while proteomics focuses on the proteins that carry out most biological functions. Taken together, they allow researchers to link genetic information to functional outcomes.
Combining these requirements in a single contract can simplify project management for a research institute. A supplier able to deliver both kinds of service can help maintain consistent quality standards, harmonise data formats and streamline turnround times across related studies. For infection biology and natural product research, this kind of joined-up molecular view can be especially important when tracking how organisms adapt or respond under different conditions.
The move also reflects a broader trend: rather than building every capacity on site, public research institutes are drawing on a market of highly specialised providers. That model can give access to the latest protocols and platforms without tying up capital budgets in fast-evolving technology.
The new contract sits within a clear pattern of research and health bodies in Europe procuring high-end sequencing and related services.
In October 2025, the Friedrich-Loeffler-Institut released a contract notice for NGS library preparation and sequencing services, explicitly targeting next generation sequencing workflows. In the same month, Helmholtz-Zentrum für Infektionsforschung GmbH went to market for pre-made libraries lane sequencing and shotgun metagenomics, highlighting demand for high-throughput analysis of complex samples.
Also in October 2025, VetAgro Sup launched a contract for the provision of sequencing services focused on medical and biological analyses, underlining that veterinary and agricultural disciplines are adopting the same tools seen in human health research.
The market has remained active. In December 2025, the Fundación Instituto de Investigación Sanitaria Illes Balears sought high-resolution genomic sequencing services for whole genome sequencing and RNA-seq across biomedical projects. By February 2026, Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE was in the market for a mass sequencing service, again indicating appetite for very high-throughput runs.
Even outside human and veterinary medicine, similar tools are being adopted. In January 2026, the Bayerische Landesanstalt für Landwirtschaft tendered for molecular genetic examinations for species identification in mixed and environmental samples, using metabarcoding approaches that rely on sequencing barcodes from complex communities.
Against this backdrop, the latest contract from the infection biology institute in March 2026 is another indicator that advanced sequencing has moved into routine procurement for a wide range of public-sector buyers.
The new call from the Leibniz institute stands out by explicitly combining sequencing with proteomics, but it is not alone in pushing beyond DNA and RNA.
In November 2025, Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca went to market for high sensitivity proteomic analysis services for 344 samples, using dual recognition technologies that combine specific antibodies with DNA detection through next generation sequencing. That notice shows how sequencing itself is increasingly used as a read-out for complex protein assays.
Transcriptomics is also entering the mainstream. In December 2025, ΕΙΔΙΚΟΣ ΛΟΓΑΡΙΑΣΜΟΣ ΚΟΝΔΥΛΙΩΝ ΕΡΕΥΝΑΣ ΑΠΘ sought services for the analysis of biological samples utilising transcriptomics methodology, emphasising gene expression profiling rather than only static genome information.
Instrumentation-focused tenders reinforce the same shift towards richer biomolecular readouts. In February 2026, Universitätsmedizin Göttingen published a notice for a system for biomolecular detection using label-free real-time analysis, while LAVES issued a contract notice in the same month for MALDI-TOF services, a technique widely used for rapid microbial identification.
Clinical and translational applications are visible too. In January 2026, Medizinische Hochschule Brandenburg CAMPUS GmbH sought providers for genetic blood testing services, tying molecular analysis directly to patient samples.
Seen together, these notices show a market that is expanding from straightforward DNA sequencing into a wider suite of proteomic, transcriptomic and advanced detection technologies. The HKI contract, with its explicit pairing of sequencing and proteomics, is aligned with that broader move towards multi-layered molecular characterisation.
Public-sector buyers are structuring their investment in molecular biology in different ways, balancing the procurement of services and capital equipment.
On the equipment side, Chem. und Veterinäruntersuchungsamt OWL has issued a notice for a Next Generation Sequencing device, while Staatsbetrieb Sächsisches Immobilien- und Baumanagement has gone to market for laboratory technology. These kinds of procurements suggest a desire to build enduring in-house capacity.
At the same time, large health systems are signalling interest in aggregated supplies of techniques rather than just machines. In February 2026, Institut Català de la Salut published a prior information notice on the aggregate supply of sequencing and other molecular biology techniques. That points towards framework-style arrangements where multiple clinical units can draw on a common pool of molecular tests.
The HKI contract clearly falls on the services side of this spectrum. Rather than specifying particular instruments, it asks the market to deliver sequencing and proteomics as complete services. Suppliers with flexible platforms, and with experience working under research and clinical governance, are likely to view this as an opportunity to extend their customer base in infection biology.
For potential bidders, the collection of recent notices offers clues about how expectations are evolving. Several buyers explicitly call for high sensitivity assays, integration of different omics layers, and support for a variety of sample types and study designs. The proteomics tender from Cluj-Napoca, with its dual-recognition and sequencing-based detection, and the transcriptomics and RNA-seq procurements show how sequencing is now embedded across many assay formats.
Suppliers positioning for the HKI contract will therefore be aware that they are competing in a market where technical capabilities are advancing quickly and where reference sites across Europe are already deploying sophisticated workflows. The ability to combine robust wet-lab processes with reliable data delivery and interpretation will be as important as headline throughput figures.
The procurement also has implications beyond individual laboratories. In February 2026, Berlin Partner für Wirtschaft und Technologie GmbH launched a contract notice for a life sciences report, indicating ongoing interest in tracking how the sector is developing. Large molecular biology contracts from research institutes such as HKI will form an important part of that picture, especially where they bring together different omics technologies under one commercial relationship.
The HKI call for molecular biological sequencing and proteomics services is short on technical detail but clear in its direction: advanced omics capabilities are now core infrastructure for infection biology and natural product research, and they are increasingly sourced through competitive service contracts.
With multiple tenders across Europe for sequencing, proteomics, transcriptomics and biomolecular detection, and with health systems exploring aggregate supplies of molecular techniques, the market for high-end analytical providers looks set to remain active. Future notices from research institutes and healthcare bodies will show whether more buyers follow HKI’s lead in bundling sequencing and proteomics, and how far integrated multi-omics procurement becomes the norm.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.